Laboratory Findings and Outcomes of Critically Ill COVID-19 Patients
Abstract
Background: COVID-19 patients have various laboratory findings associated with severe conditions and higher mortality rates. We conducted this study to evaluate the laboratory changes and their effect on the mortality of critically ill patients with COVID 19.
Methods: This cohort study evaluated the laboratory changes in 192 patients admitted to intensive care units of Imam Khomeini hospital complex, Tehran, Iran. The patients with manifestations of severe COVID-19 of both sexes and older than 16 years were enrolled in the study. The primary outcome was the laboratory changes, and the secondary outcome was the death or survival of the patients. The laboratory data were recorded on the admission day, followed daily by the changes and the neutrophil-lymphocyte ratio (NLR). The laboratory changes of two groups of survived or non-survived patients were compared by chi-square for categorical variables. An independent sample t-test was applied to study the differences between the two groups' continuous variables. Values are shown as mean±SD.
Results: Of all the 192 patients, 123 (64.06%) were male, and 69 (35.93%) were female. The survived group was 86 (44.79%), and the non-survived group was 106 (55.20%). Age (62.31±13.77), sex, and BMI (27.34±4.63) were not significantly different in the two groups (P value= .248, .368, and .444, respectively). NLR, lactate dehydrogenase/lymphocyte (LDH/LYM) ratio were significantly different in the two groups (P value= .000, .004, respectively).
Conclusion: COVID-19 patients have a variety of laboratory findings. NLR and LDH/LYM ratios have a prognostic value in severe COVID-19 patients.
[2] World Health Organization. (https://www.who.int/emergencies/diseases/novel-coronavirus-2019).
[3] Figliozzi S, Masci PG, Ahmadi N, Tondi L, Koutli E, Aimo A, et al. Predictors of adverse prognosis in COVID‐19: a systematic review and meta‐analysis. Eur J Clin Invest. 2020; 50(10):e13362.
[4] Pourbagheri-Sigaroodi A, Bashash D, Fateh F, Abolghasemi H. Laboratory findings in COVID-19 diagnosis and prognosis. Clin Chim Acta. 2020; 510:475-82.
[5] Zhang ZL, Hou YL, Li DT, Li FZ. Laboratory findings of COVID-19: a systematic review and meta-analysis. Scandinavian journal of clinical and laboratory investigation. 2020; 80(6):441-7.
[6] Xie Y, Wang Z, Liao H, Marley G, Wu D, Tang W. Epidemiologic, clinical, and laboratory findings of the COVID-19 in the current pandemic: systematic review and meta-analysis. BMC infectious diseases. 2020; 20(1):1-2.
[7] Khamis AH, Jaber M, Azar A, AlQahtani F, Bishawi K, Shanably A. Clinical and laboratory findings of COVID-19: A systematic review and meta-analysis. J Formos Med Assoc. 2021; 120(9):1706-18.
[8] Lippi G, Plebani M. The critical role of laboratory medicine during coronavirus disease 2019 (COVID-19) and other viral outbreaks. Clin Chem Lab Med. 2020; 58(7):1063-9.
[9] Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The lancet. 2020; 395(10223):497-506.
[10] Lagadinou M, Salomou EE, Zareifopoulos N, Marangos M, Gogos C, Velissaris D. Prognosis of COVID-19: Changes in laboratory parameters. Age (yrs). 2020; 62(13.4):47-16.
[11] Martha JW, Wibowo A, Pranata R. Prognostic value of elevated lactate dehydrogenase in patients with COVID-19: a systematic review and meta-analysis. Postgrad Med J. 2022; 98(1160):422-427.
[12] Serin I, Sari ND, Dogu MH, Acikel SD, Babur G, Ulusoy A, et al. A new parameter in COVID-19 pandemic: initial lactate dehydrogenase (LDH)/Lymphocyte ratio for diagnosis and mortality. J Infect Public Health. 2020; 13(11):1664-70.
| Files | ||
| Issue | Vol 9 No 2 (2023): Spring |
|
| Section | Research Article(s) | |
| DOI | https://doi.org/10.18502/aacc.v9i2.12507 | |
| Keywords | ||
| Laboratory COVID-19 Critically ill outcomes | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
